Renzenbrink & Partner advises Bruker Corporation on the acquisition of JPK Instruments AG

7 July 2018

Renzenbrink & Partner has advised Bruker Corporation on the acquisition of JPK Instruments AG, a leading manufacturer of nanoanalytic instruments.
Headquartered in Berlin, JPK provides microscopy instrumentation for biomolecular and cellular imaging, as well as force measurements on single molecules, cells and tissues.

With nearly $2 billion in revenues and more than 6,000 employees worldwide, NASDAQ-listed Bruker Corporation is a global manufacturer of high-end analytical instruments used within the academic & government, pharma/biotech, clinical diagnostic, and industrial markets. The company operates in the life science tools & diagnostics industry and has developed a strong brand for innovation and quality. JPK’s offerings and life science applications expertise are synergistic with Bruker’s existing portfolio of advanced fluorescence microscopy products.

Renzenbrink & Partner has advised Bruker Corporation on all legal aspects of the acquisition. The team of Renzenbrink & Partner consisted of partners Dr Andreas Stoll (M&A/Corporate), Marc H. Kotyrba (Tax) and Dr Gunnar Schmüser (Finance) as well as associates Dr Alexander Haunschild, Dr Niels Maier and Dr Florian Seitz.

For labor law aspects, Renzenbrink & Partner cooperated with Dr Holger Meyer and Sophie Kuske of law firm Schramm Meyer Kuhnke. IP law aspects were addressed by Dr Kai-Uwe Plath and Dr Jan-Michael Grages of the firm KNPZ, while Dr Andreas Hahn of law firm Oppenländer advised on competition law aspects.